Anti-angiogenic therapeutic drugs for treatment of human cancer

Journal of Cancer Molecules

Volumn 4, Issue 2, 2008, Pages 37-45

  Wu, Han Chung ^a   Huang, Chia Ting ^a   Chang, De Kuan ^a  

^a INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

Angiogenesis; Anti angiogenic therapy; Toxicity; Vasculogenic mimicry

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BCR ABL PROTEIN; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; LAPATINIB; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RITUXIMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; VITRONECTIN RECEPTOR;

ANGIOGENESIS; BLEEDING; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG TARGETING; EDEMA; EXTRACELLULAR MATRIX; FATIGUE; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INJECTION SITE REACTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PROTEINURIA; QUALITY OF LIFE; REVIEW; RIGOR; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; TACHYCARDIA; THROMBOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; WOUND HEALING IMPAIRMENT;

EID: 46149103673     PISSN: 18160735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers 8, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
2. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10: 3577-3585, 2004.
3. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006.
4. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
5. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475-485, 2007.
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 438; 967-974, 2005.
7. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60; 1878-1886, 2000.
8. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047, 2000.
9. Belotti D, Vergani V, Drudis T, Borsottl P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.
10. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
11. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94: 4143-4155, 1999.
12. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14: 13-19, 2003.
13. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63; 4342-4346, 2003.
14. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, Sessa WC, Gerweck LE, Jain RK, Fukumura D. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 14: 255-257, 2008.
15. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8: 309-316, 2008.
16. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
17. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6; 273-286, 2007.
18. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859-870, 2006.
19. Morin MJ. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19: 6574-6583, 2000.
20. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
21. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082, 1990.
22. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (ST1571, imatinib), a razionaliy developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502, 2002.
23. Leary A, Johnston SR. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 25: 347-365, 2007.
24. Dimetri GD, van Oosterom AT, Garrett CR, Btackstein ME, Shah MA, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Pesai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006.
25. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
26. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524, 2006.
27. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745, 2007.
28. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Phase II1 placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512, 2006.
29. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 18: 615-621, 2006.
30. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134; 379, 2008.
31. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasul H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 103: 19478-19483, 2006.
32. Sonpavde G, Hutson TE. Pazopsnib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9: 115-119, 2007.
33. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17: 253-261, 2008.
34. Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 42: 441-453, 2006.
35. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov 6: 431-432, 2007.
36. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-ErbB tyrosine kinase inhibitor. Semin Oncol 28: 80-85, 2001.
37. Janne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small cell lung cancer. J Clin Oncol 25: 3936-3944, 2007.
38. Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84: 3439-3443, 1987.
39. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 332; 323-327, 1988.
40. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6: 349-356, 2007.
41. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12: 4421 s-4425s, 2006.
42. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13: 1845-1857, 2006.
43. 3 for angiogenesis. Science 264: 569-571, 1994.
44. 3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 5: 3122-3129, 2006.
45. 3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11: 7851-7860, 2005.
46. Dass CR, Tran TM, Choong PF. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. J Dent Res 86: 927-936, 2007.
47. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 16: 901-906, 1994.
48. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23: 217-225, 1984.
49. Dekker RJ. Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, Meijers JC, Voorberg J, Pannekoek H, Horrevoets AJ. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 107: 4354-4363, 2006.
50. Folkman J, Kalluri R. Cancer without disease. Nature 427: 787, 2004.
51. Verheul HM, Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 10: 403-412, 2005.
52. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97: 1427-1434, 2001.
53. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150-4166, 1998.
54. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/ vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22: 1500-1505, 2002.
55. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors; determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
56. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adriane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
57. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23: 1295-1311, 2005.
58. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40, 2006.
59. Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20: 1657-1667, 2002.
60. Mross K, Stelnbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43: 55-63, 2007.
61. Kabbinavar F, Hurwitz HI, Fehrenbacher L., Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
62. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Invest Drugs15: 553-561, 2006.
63. Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K, Kyrie PA. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 19: 1757-1760, 1999.
64. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91; 173-180, 2005.
65. Ma L, Ellioti SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets, modulate gastric ulcer healing. role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 98: 6470-6475, 2001.
66. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001.
67. Bombeli T, Karsan A, Tait JF, Harlon JM. Apoptotic vascular endothelial cells become procoagulant. Blood 89: 2429-2442, 1997.
68. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35, 2006.
69. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105: 986-993, 2005.
70. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24: 1363-1369, 2006.
71. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660-664, 2006.
72. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000, 2001.
73. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69: 1986-1995, 2006.
74. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFIt-1) induces proteinuria. J Biol Chem 278: 12605-12608, 2003.
75. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008.
76. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491-500, 2005.
77. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55: 5687-5692, 1995.
78. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958, 2000.
79. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23: 263-272, 2001.
80. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421, 2003.
81. Shubik P, Warren BA. Additional literature on "vasculogenic mimicry" not cited. Am J Pathol 156: 736, 2000.
82. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors; frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97: 14608-14613, 2000.
83. Maniotis AJ, Chen X, Garcia C, DeChristopher PJ, Wu D, Pe'er J, Folberg R. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab Invest 82: 1031-1043, 2002.
84. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91: 359-367, 1999.
85. Thies A, Mangold U, Moll I, Schumacher U. PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol 195: 537-542, 2001.
86. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ. Molecular determinants of ovarian cancer plasticity. Am J Pathol 158: 1279-1288, 2001.
87. Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther 1; 511-517, 2002.
88. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 8018-8023, 2001.
89. Hendrix MJ, Seftor EA, Kirschmann DA, Seftor RE. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res 2: 417-422, 2000.
90. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM Jr, Cohen MB, Lubaroff DM, Hendrix MJ. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 50: 189-201, 2002.
91. Hattori H. Atypical lipomatous tumor of the lip with pleomorphic lipoma-like myxoid area, clinically simulating mucocele. J Oral Pathol Med 31: 561-564, 2002.
92. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao, JX. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE 3: e1652, 2008.
93. Clarils R, Schalkwijk L, Ruiter DJ, de Waal RM. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Invest Ophthalmol Vis Sci 42: 1422-1428, 2001.
94. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangio-genesis in health and disease. Cancer Cell 1: 219-227, 2002.
95. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883-1886, 2002.
96. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC, Kuo ML. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9: 209-223, 2006.
97. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751-755, 2002.
98. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651 2002.
99. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36: 55-63, 1996.
100. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 303: 1818-1822, 2004.
101. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42: 419-436 2003.
102. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67: 10958-10965, 2007.
103. Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 64: 8002-8008, 2004.
104. Lo A, Lin CT, Wu HC. Hepatocellular carcinoma cell-specific peptied ligand for targeted drug delivery. Mol Cancer Ther 7: 579-89, 2008.
105. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156: 1363-1380, 2000.
106. Wu HC, Chang DK, Huang CT. Targeted therapy for cancer. J Cancer Mol 2: 57-66, 2006.
107. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306, 2003.
108. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10: 461-466, 2005.
109. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450, 2007.
110. Habeck M. FDA licences imatinib mesylate for CML. Lancet Oncol 3: 6, 2002.
111. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12: 107-113, 2007.
112. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9: 1323-1332, 2003.
113. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 67: 593-599, 2007.